George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Ralph
Some people are very off in their time frames
Imagine only waiting 2 days !!
U am adding more from profits elsewhere
363035 was bought on Tuesday for 4.68, sold today for 4.52, they should have sold on Wednesday for 5.
Yes, they are one of Frances leading healthcare companies
Is that who we work with ?
These "low" value trades appear here all the time.
https://www.servier.us/research-and-development/oncology-pipeline any of the drugs listed here PYC could be working on with Servier as per RNS in April.
Good morning Kidlington, I don't think someone would buy and sell £5 pound of PYC when dealing costs are £9.95 , more likely an error or maybe something else
The momentum is certainly with PYC l12mths and myself and husband are adding more here and to income stocks amd other medical stocks particularly
marketing, including in social media and other marketing channels, together with the increased business development capacity resulting from the hire of a dedicated professional have helped the Company to minimise the time between first contact with a potential new client and signing of contracts. In addition, significant new clients have been attracted as a result of the Company's positive reputation and/or by personal recommendation by existing or past clients. In the six months ended 31 December 2021 alone, the Company signed eleven agreements of various sizes with existing and new clients (including three with Merck KGaA which were the subject of an RNS on 13 December 2021).
The Company currently has contracted revenues of around £460k for the current half year ended 30 June 2022. This is the highest level of contracted revenue for H2 ever recorded by the Company at this point in any financial year and does not account for any further projects that may be signed and commenced during the remainder of this current financial year.
A 98 trade was last trade yesterday and also today, probably the same person, selling at a loss?
Welcome L:aura btw.
Thankyou Truro
I have noticed their revenues are increasing as are their clients and also growing awareness from companies sabout their work
I think £6mln is too low for what they have shown the last 18mths and what thebl comapny looks like delivering 2022
I just ignore trouble makers on all the boards I'm invested in
Hi Laura, there are some strange posters on here some of whom live in the past. If you look at the last 2 years annual accounts and also this years interims you may see a thread that is building on our traditional consulting role but also starting to move into new arears such as clinical trials and commercial collaborations. A couple of years ago they had a brainstorming session with outside consultants and this seemed to give the company a bit of a boost. As always nothing is guaranteed but it is difficult to see anything other than rising revenues and the cost base is pretty tightly controlled. Add a USP into the mix and this could get quite interesting!
Let’s not forget that a £6m valuation is multiples of the balance sheet value for a company that could probably hold its staff meetings in a telephone kiosk….. In reality there isn’t really anything to support a valuation of that amount - the company has never posted a profit, if it wasn’t for fundraising it would be under the water by now.
I’ve been invested and followed for 15 years and nothing has changed - every day week, month and year the same old rhetoric on here.
go and look in the dmtr archive all the research you ned his there
Thanks Steve
Will need to do more research over the weekend but if you are able to summarise what may be ahead for 2022 that would be most welcome
I can see that they are hoping for more partnerships or contracts contianed within the recent results and I notice they are winning more contracts last 12mths than before...is there any reason for this ?
Welcome Laura
I for one am confident the deals are coming, its all pointing to that in the various RNS's.. Happy to hold over 1% of the company now !
Thanks Trumpton
I can see that PYC clients are very diverse and growing over the last 2yrs , I am invested in SCLP and I cannot believe PYC only valued at 6 million given what they can offer
If it is someone like GlaxoSmithKline that would be a real breakthrough
Thanks for replying
Well the CEO and major holder Zahid Ali both have worked at GSK !!
My husband is in the health care industry and there is a huge impetus to make up for lost time due to covid in terms of oncology, drug trial recruitment and drug development,
Many in the industry are realising that they don't need to be as archaic as they have been for the last few decades , and the 18mth turnaround in creating a covid vaccine plus the negative impact covid has had on drug trials and development has highlighted the way the industry needs to move forward. The Uk and USA particularly have committed to tackling Cancer once and for all
I have therefore become interested
in several UK bio tech/A.I /oncology stocks
I have taken a first small buy today after reading the last few pieces of news
Does anyone know who the large contract may be with ?
Thanks
About to break ? NT @ 5p
top end of bollinger band ,game on IF it breaks above 5.20
This is the 3rd appointment in the last 9 months or so. Considering the length of time some appointments can take this shows a definite focus on recruitment. There's much more of a sense of purpose recently. The August appointment of Hayley Close as head of business development was, for me, an important step and she seems to be having the desired effect on our pipeline. Maybe PYC's time is about to come. This could move quite quickly but not as a spike but in a sustained way. Mind you I did quite nicely in the previous spike but now I want sustained growth.
Lovely... Why expand the team if we werent expecting big growth ?
His details already on Pyc site, has 7 years experience.
https://www.physiomics.co.uk/about/team/
Quite a few appointments in the last 9 months.
#Val deal allegedly due June 2022.
RNS…https://www.lse.co.uk/rns/PYC/physiomics-expands-technical-team-h1l32wy11dsuxxq.html
40k buy limits yesterday at the close.. due explosive move
Should go well today NT 5p at the close yesterday large bid again.. news on big pharma could drop any day ??
Are we getting closer to the "Large Pharma" contract mooted about a few months ago? Discussions have been going on at that time for over 12 months, we must be in 15mth area now. JM does say that "if" it comes off, it could be like another "Merck" ie repeat business and on several fronts.
Still awaiting confirmation om who is going to buy DosemeRx from TRHC, JM says that whatever happens there, he believes it will have no negative affect om PYC and their relationship.
The NIHR prostate cancer decision tool trial i believe will have been completed at the end of April 2022, so a update on that trial should be forthcoming,
Like a few i am perplexed with the share options RNS last week. There was a RNS in March 21 about options at 7.55. Last week the options were priced at 4.38.
Yesterday we had a nice 13% rise, in part by someone buying £12k worth. that is the biggest buy sine the 500k trade around 4p . Are these buyer(s) looking at value, technical's or long term? £12k seems too much for a "punt" to me.